Cash Flow Statement

Amortization of Deferred Charges Amortization of Deferred Charges Amortizatization of Intangibles Amortizatization of Intangibles Capital Expenditures Capital Expenditures Cash from Financing Activities Cash from Financing Activities Cash from Investing Activities Cash from Investing Activities Cash from Operations Cash from Operations Change in Account Payables Change in Account Payables Change in Accured Expenses Change in Accured Expenses Change in Acquisitions & Divestments Change in Acquisitions & Divestments Change in Cash Change in Receivables Change in Receivables Depreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and Depletion Depreciation and Depletion Free Cash Flow Free Cash Flow Gains from Investment Securities Gains from Investment Securities Gains from Sales and Divestitures Gains from Sales and Divestitures Long-Term Debt Issuances Net Cash Flow Net Cash Flow Net Income Non-cash Items Non-cash Items Other financing activities Other financing activities Share-based Compensation Share-based Compensation Shares Issued

Daily Values

Growth Metrics

Others

Maze Therapeutics (MAZE) Gains from Sales and Divestitures (2024 - 2025)

Maze Therapeutics' Gains from Sales and Divestitures history spans 2 years, with the latest figure at $1.1 million for Q4 2025.

On a quarterly basis, Gains from Sales and Divestitures rose 4198.55% to $1.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $1.1 million, a 4198.55% increase, with the full-year FY2025 number at $1.1 million, up 4198.55% from a year prior.
Gains from Sales and Divestitures hit $1.1 million in Q4 2025 for Maze Therapeutics, up from $25930.0 in the prior quarter.
Over the last five years, Gains from Sales and Divestitures for MAZE hit a ceiling of $1.1 million in Q4 2025 and a floor of $25930.0 in Q4 2024.